<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Vrabec R</submitter><funding>European Union</funding><funding>Ministry of Education Youth and Sports</funding><pagination>4399</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10003045</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(5)</volume><pubmed_abstract>Alzheimer's disease (AD) is the most common cause of dementia in elderly people; currently, there is no efficient treatment. Considering the increase in life expectancy worldwide AD rates are predicted to increase enormously, and thus the search for new AD drugs is urgently needed. A great amount of experimental and clinical evidence indicated that AD is a complex disorder characterized by widespread neurodegeneration of the CNS, with major involvement of the cholinergic system, causing progressive cognitive decline and dementia. The current treatment, based on the cholinergic hypothesis, is only symptomatic and mainly involves the restoration of acetylcholine (ACh) levels through the inhibition of acetylcholinesterase (AChE). Since the introduction of the Amaryllidaceae alkaloid galantham</pubmed_abstract><journal>International journal of molecular sciences</journal><pubmed_title>Natural Alkaloids as Multi-Target Compounds towards Factors Implicated in Alzheimer's Disease.</pubmed_title><pmcid>PMC10003045</pmcid><funding_grant_id>CZ.02.1.01/0.0/0.0/18_069/0010046</funding_grant_id><pubmed_authors>Cahlikova L</pubmed_authors><pubmed_authors>Blunden G</pubmed_authors><pubmed_authors>Vrabec R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Natural Alkaloids as Multi-Target Compounds towards Factors Implicated in Alzheimer's Disease.</name><description>Alzheimer's disease (AD) is the most common cause of dementia in elderly people; currently, there is no efficient treatment. Considering the increase in life expectancy worldwide AD rates are predicted to increase enormously, and thus the search for new AD drugs is urgently needed. A great amount of experimental and clinical evidence indicated that AD is a complex disorder characterized by widespread neurodegeneration of the CNS, with major involvement of the cholinergic system, causing progressive cognitive decline and dementia. The current treatment, based on the cholinergic hypothesis, is only symptomatic and mainly involves the restoration of acetylcholine (ACh) levels through the inhibition of acetylcholinesterase (AChE). Since the introduction of the Amaryllidaceae alkaloid galantham</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Feb</publication><modification>2025-04-04T03:41:54.574Z</modification><creation>2025-04-04T03:41:54.574Z</creation></dates><accession>S-EPMC10003045</accession><cross_references><pubmed>36901826</pubmed><doi>10.3390/ijms24054399</doi></cross_references></HashMap>